CPL-M1-SEM 10mg (Incretin Research)
Original price was: $ 100.00.$ 79.00Current price is: $ 79.00.
The GLP-1 Benchmark. 11,000+ Trial Participants.
Semaglutide is the most extensively studied GLP-1 receptor agonist in clinical research. Its trial program — spanning the STEP and SELECT series — represents the largest body of published evidence for any incretin-based compound.
Why Researchers Study It
- GLP-1 receptor activation — cAMP/PKA signaling cascade
- STEP trials — 1,961+ participants across Phase 3 studies
- Once-weekly dosing — extended half-life via DPP-4 resistance
- SELECT trial — 17,604 participant cardiovascular outcomes study
What Makes It Different
Semaglutide established the benchmark that every subsequent GLP-1 compound is measured against. The STEP and SELECT trial programs represent the most comprehensive clinical dataset in incretin research.
Analytical Documentation
- Purity: Batch-specific Certificate of Analysis (COA) included
- Method: HPLC and/or LC-MS verification
- Storage: Lyophilized — store cool, dry, protected from light
⚠️ For research use only. Not for human consumption. Not for therapeutic, diagnostic, or veterinary application. Researchers are responsible for compliance with applicable regulations.
Choice Peptide Labs – Certificate of Analysis
Product: Semaglutide
Strength: 5mg
Batch / Lot: PB-2026-SEM-0317
COA Date: Mar 24, 2026
Product Information
Testing laboratory / source: Data derived from supplier COA (Aodt Peptides)
Appearance: White lyophilized powder
Storage: -20°C, dry, dark
Analytical Results
Purity: 99.2%
Analytical method: RP-HPLC / ESI-MS
Result summary: Purity meets or exceeds internal specification for research use.
Conform/Pass: BATCH RELEASED — All tests conform to specifications
Notes
This certificate summarizes analytical data provided by the original testing laboratory. Minor
formatting or language changes have been made for consistency.
Disclaimer
For laboratory research use only. Not for human or animal consumption. No therapeutic or
diagnostic use.
